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ABSTRACT
Introduction: The COVID-19 pandemic has dramatically challenged the national health systems world-
wide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified 
weekly administration regimens, thus representing a promising option for the outpatient treatment of 
Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for 
the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data 
seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and 
infective endocarditis.
Areas covered: A search in the literature using validated keywords (dalbavancin, Gram-positive infec-
tions, Gram-positive cocci, ABSSSI, intravenous treatment, and long-acting antibiotics) was conducted 
on biomedical bibliographic databases (PubMed and Embase) from 2004 to 30 September 2020. Results 
were analyzed during two consensus conferences with the aim to review the current evidence on 
dalbavancin in Gram-positive infections, mainly ABSSSI, osteomyelitis, and infective endocarditis, high-
light the main limitations of available studies and suggest possible advantages of the molecule.
Expert opinion: The board identifies some specific subgroups of patients with ABSSSIs who could 
mostly benefit from a treatment with dalbavancin and agrees that the design of homogenous and 
robust studies would allow a broader use of dalbavancin even in other clinical settings.
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The outbreak of severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) infection has represented an enormous 
challenge to the national health systems worldwide. During 
the first months of the epidemic, the high number of COVID- 
19 patients requiring hospitalization and intensive care sup-
port has caused a drastic reorganization of the health-care 
facilities, thus allowing an appropriate response to the epide-
miological emergency, but also compromising the possibility 
to face adequately other medical needs unrelated to the SARS- 
CoV-2 epidemic. Nonetheless, the spread of the infection in 
the population has been better kept under control in areas 
where a community-based model was promptly adopted, 
namely a system based on an accurate contact-tracing activity, 
on isolation of positive cases, on home-care for patients with 
mild or no symptoms and on inpatient-care for patients with 
a severe COVID-19 disease. On the contrary, the hospital-based 
model has shown to be mostly ineffective, leading to 
a premature overload of hospital facilities [1,2]. In Italy, the 
National Healthcare Service is regionally based, with local 
authorities responsible for the organization and delivery of 
health services, leaving the Italian Government with a weak 
strategic leadership. This decentralization and fragmentation 
of health services seems to have restricted timely interven-
tions and effectiveness [3]. Notably, avoiding unnecessary 
hospitalization and delays in the discharge of patients may 
be an efficient long-term strategy to cope adequately with the 
persistent spread of the virus in the communities. However, it 
requires a coherent strengthening of territorial services, 
including general practitioners, home care and diagnostic 
centers. Furthermore, the decentralization of medical services 
imposed by the lasting pandemic could also serve as a chance 
to deal with some old limits of the hospital-based health-care 
systems, such as nosocomial infections from multidrug- 
resistant pathogens, which are often more severe in frail and 
old patients [4]. Within this context, the employment of long- 
CONTACT Mario Venditti mario.venditti@uniroma1.it Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazza Aldo Moro 
5, Roma (RM) 00185 Italy
*All authors contributed equally to the manuscript and are therefore listed alphabetically.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY                                                                                                                 
https://doi.org/10.1080/14787210.2021.1894130
© 2021 Informa UK Limited, trading as Taylor & Francis Group
acting antimicrobial agents could represent a unique way to 
discharge patients early or to treat infections in an outpatient 
setting, consequently leading to a reduction of assistance 
costs and a reduction of nosocomial infections (as well as 
the possibility of acquiring COVID-19 in the hospital setting). 
Dalbavancin is a novel semisynthetic antimicrobial agent 
belonging to the second-generation lipoglycopeptides family.
By binding to the D-alanyl-D-alanine terminus of growing 
peptidoglycan chains, dalbavancin interferes with cross-linking 
and inhibits bacterial cell wall synthesis of Gram-positives. 
Dalbavancin has a broad range of activity, and MIC50/90 values 
against Staphylococcus aureus (MIC50/90 0,03 mg/L for both 
MSSA and MRSA), vancomycin-susceptible Enterococcus faeca-
lis (MIC50/90, 0.03/0.06 mg/L), β-hemolytic streptococci 
(MIC50/90, 0.008/0.015 mg/L), and Streptococcus anginosus 
group (MIC50/90, ≤0.004/≤0.004 mg/L) remained stable since 
its clinical approval up to date [5]. Preclinical studies have 
shown that the pharmacodynamic determinant of dalbavancin 
that best correlated with antibacterial activity is the area under 
the concentration–time curve (AUC): MIC ratio, with the great-
est net reduction in the log10 of colony forming units occur-
ring when large doses were administered less frequently. 
Dalbavancin has a favorable pharmacokinetic profile with 
high plasma protein binding, low likelihood for drug–drug 
interactions and a very long elimination half-life. Overall, this 
unique pharmacokinetic/pharmacodynamics (PK/PD) profile 
makes once weekly dosing for managing severe infections 
feasible. After single 1500 mg dose, the free plasma concen-
trations of dalbavancin persisted higher than the MIC clinical 
breakpoints of various species of Staphylococci and 
Streptococci including MDR strains [6,7]. This might explain 
why, to our knowledge, nowadays there are only two cases 
describing the development of dalbavancin breakthrough 
resistance during, or immediately after therapy [8,9]. 
Although the potentially underlying mechanisms of the dal-
bavancin MIC increase are not yet fully understood, they could 
be due to a thickening of bacterial cell-wall [9].On the other 
hand, a topical and interesting in vitro and in vivo activity of 
dalbavancin toward SARS-CoV-2 was recently highlighted [8], 
suggesting a potential role in the treatment of COVID-19 [9]
Nevertheless, the approved indications for dalbavancin by 
the FDA and the EMA are for the treatment of acute bacterial 
skin and skin structure infections (ABSSSI), although in clinical 
practice smaller lesions can also be found (e.g. 8 × 8 cm cuta-
neous abscess or wound infection that is relatively large 
despite it does not meet the FDA definition).
Besides being a valid choice in the treatment of skin and 
soft tissue infections, there is a growing amount of evidence 
that dalbavancin could be useful in other invasive Gram- 
positive infections that need prolonged intravenous treat-
ments, including osteomyelitis, prosthetic joint infections, 
infective endocarditis and catheter-related bacteremia [10]. 
Retrospective analyses of patients with these types of infec-
tions being treated with dalbavancin showed a favorable out-
come in most cases and an excellent safety profile. The 
efficacy of dalbavancin was also proved in vulnerable patients 
with osteomyelitis or non-complicated bacteremia in whom 
a first-line antimicrobial therapy had been ineffective [11]. 
A sequential successful use of dalbavancin in patients with 
infective endocarditis was also reported [12]. Lastly, pharma-
coeconomic analyses show that long-acting antimicrobial 
agents like dalbavancin are associated with a significant 
decrease of hospitalization days and therefore with 
a considerable costs reduction to the health-care services 
[13,14]. However, the real impact on clinical practice is never-
theless hampered by the extremely variable administration 
regimens reported (ranging from a single 1500 mg injection 
to a 7-week lasting weekly administration regimen) and the 
intrinsic diversity of the included Gram-positive infections, 
rendering them hard to be analyzed in a single retrospective 
study with common primary outcomes and follow-up time 
points [13,15].
This paper aims to review the literature and highlight the 
features of patients who could mostly benefit from an anti-
microbial therapy with dalbavancin and to clarify the dosage 
and the duration of treatment which showed the most pro-
mising efficacy for each case.
2. Methods
In order to review the literature on the potential uses of 
dalbavancin, including on and off-label indications, like non- 
ABSSSI infections, and to assess the most suitable administra-
tion regimens, a group of experts was organized. Specialists 
belonging to different medical areas convened, namely infec-
tious diseases (ID) specialists and a clinical pharmacologist. 
A total of two consensus conferences took place during 
which the available evidence on dalbavancin were evaluated. 
Specifically, a search in the literature using validated keywords 
filters to select articles regarding dalbavancin was performed: 
dalbavancin, Gram-positive infections, Gram-positive cocci, 
ABSSSI, intravenous treatment, and long-acting antibiotics. 
A literature research on biomedical bibliographic databases 
(PubMed and Embase) was carried out from the year 2004 
up to 30 September 2020, and research papers, reviews, and 
Article highlights
● The COVID-19 pandemic has dramatically challenged the national 
health systems imposing measures for the reduction of hospitalisa-
tion and the implementation of territorial medicine to reduce the 
spread of in-hospital infections
● Many scientific publications are now available concerning the off- 
label use of dalbavancin for osteomyelitis, prosthetic joint infections, 
and infective endocarditis despite dalbavancin being a long-acting 
lipoglycopeptide approved for the treatment of ABSSSI
● The pharmacokinetic and pharmacodynamic properties of dalbavan-
cin allow therapy schedules suitable for the treatment of subacute- 
chronic osteomyelitis, prosthetic joint infections, and infective endo-
carditis and also after clinical stabilization in acute forms as an 
alternative to oral treatment.
● Evidence of dalbavancin use in osteomyelitis and infective endocar-
ditis are promising but considering the heterogeneity of the available 
studies and the limitations regarding inclusion criteria, administration 
regimens, outcome measures, and follow-up durations, more 
research is needed to standardize and increase the use of dalbavan-
cin in indications other than ABSSSIs.
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ABSSSIs have been recently defined by the FDA as bacterial 
infections of the skin with a lesion size area of at least 75 cm2 
(lesion size measured by the area of redness, edema or indura-
tion). In this group, cellulitis, erysipelas, wound infections and 
major cutaneous abscesses are therefore included. However, it 
still represents an extremely heterogenous group of diseases 
in terms of prognosis, ranging from mild to potentially life- 
threatening infections [16]. ABSSSIs are generally caused by 
Gram-positive bacteria, particularly Staphylococcus aureus and 
Streptococcus spp. In the previous classification of skin and soft 
tissue infections (SSTIs), the infection may involve the subcu-
taneous tissue and is potentially attributed to a broader range 
of pathogens, such as Gram-positive, Gram-negative and anae-
robic bacteria [17]. In order to ensure an implementation of 
antimicrobial stewardship programs (ASPs), etiologic diagnosis 
represents a milestone in the clinical approach to ABSSSIs. 
With this aim, biological samples should be obtained through 
needle aspiration, in case of systemic infection, blood culture 
[18]. Due to their bacterial etiology, ABSSSIs are generally 
treated with empiric antibiotic treatment mainly targeting 
Gram-positive cocci. Moreover, ABSSSIs may require surgical 
intervention like drainage or debridment, due to the presence 
of necrotic tissue [17]. Unfortunately, an increasing rate of 
ABSSSIs is caused by multidrug-resistant pathogens, such as 
methicillin-resistant Staphylococcus aureus (MRSA), thus often 
requiring second-level antibiotic regimens [18]. Thanks to its 
spectrum of activity and peculiar pharmacokinetic properties, 
dalbavancin turned out to be effective in the treatment of 
ABSSSIs in two different administration regimens: a single 
1500 mg dose or a two-doses (1000 mg at day 1 and 
500 mg at day 8) regimen [19,20].
3.2. Osteomyelitis
Osteomyelitis are a constellation of inflammatory processes, 
based on different pathogenetic mechanisms, accompanied 
by bone destruction and caused by an infecting microorgan-
ism [21]. Based on the mechanism of infection, osteomyelitis 
can be classified in hematogenous and non-hematogenous, 
which includes iatrogenic, traumatic and contiguity osteomye-
litis. Moreover, due to the duration of the illness, osteomyelitis 
can be further classified in acute or chronic. Hematogenous 
osteomyelitis are normally monomicrobial, whereas non- 
hematogenous cases can be monomicrobial or caused by 
a multitude of pathogens. In both types of osteomyelitis, the 
most frequently isolated bacteria are Staphylococcus aureus, 
coagulase-negative staphylococci, and streptococci [22]. 
Gram-negative and anaerobic bacteria are a rare cause of 
osteomyelitis in adults [23]. Prosthetic joint infection (PJI) is 
one of the most frequent complications of joint replacement 
surgery. Depending on the timing of the infection in relation 
to the surgery, PJI can be categorized as early, delayed or late 
onset. While early and late onset infections are often caused 
by Staphylococcus aureus, Gram-negative or anaerobic bac-
teria, delayed onset PJIs are generally attributed to coagulase- 
negative staphylococci [24]. As previously stated, osteomyelitis 
and PJIs are not currently approved indications for the use of 
dalbavancin. Nonetheless, the off-label use of this agent in 
these two clinical settings has been extensively reported in 
clinical trials and real-word observational studies (Table 1).
Dunne and coworkers realized a population pharmacoki-
netic model to predict the dalbavancin concentrations theore-
tically achievable into bone and articular tissue after the 
administration of two 1500 mg doses 1 week apart. The find-
ings suggested that this administration schedule would allow 
the achievement of high enough drug concentrations in 
blood, bone and synovial fluids for up to 8 weeks, thus pro-
viding a theoretical rationale for the use of dalbavancin in the 
treatment of osteomyelitis and PJI [6]. Furthermore, dalbavan-
cin showed potent in vitro activity with low MIC values against 
the most commonly isolated pathogens in osteomyelitis and 
PJI: the MIC50 for MRSA, MSSA, MRSE, and MSSE was 0.03 mg/ 
L, the MIC90 for MRSA and MSSA was 0.06 mg/L and for MRSE 
and MSSE 0.12 mg/L and MSSE; the MIC50/90 for vancomycin- 
susceptible (VS) E. faecalis and E. faecium were 0.03 and 
0.125 μg/mL, respectively (range, ≤0.016–0.125 mg/L) [25,26]. 
Finally, preliminary in vitro and animal model data also sup-
port a potential activity of dalbavancin against bacterial bio-
films, which are thought to have a significant pathogenetic 
role in bone and joint infections (Minimum Biofilm Bactericidal 
Concentration – MBBC50 for MRSA, MSSA, MRSE and MSSE was 
1 mg/L; MBBC90 for MRSA and MSSA was 2 mg/L and for MRSE 
and MSSE 4 mg/L; and MBBC50/90 for VS E. faecalis and 
E. faecium 0.5 and 1 mg/L, respectively) [25–27].
Currently, available clinical data on the use of dalbavancin in 
osteomyelitis and PJI are coworkers analyzed medical records of 
patients treated with dalbavancin affected by osteomyelitis 
(n = 12) and PJI (n = 20), mostly caused by methicillin-susceptible 
Staphylococcus aureus (MSSA), MRSA and coagulase-negative 
Staphylococci [14]. The large majority of patients included (97,1%) 
had already received a prior antibiotic therapy and the reasons to 
switch to dalbavancin were mostly related to an easier antibiotic 
administration or to the failure of the previous therapy. 
Dalbavancin was found to be effective in most of the patients 
with osteomyelitis (91,7%) and PJI (80%) based on the absence of 
clinical and microbiological evidence of infection during the fol-
low-up period (>1 month). Another study reported similar data 
based on a copious cohort of 30 patients with osteomyelitis and 32 
patients with PJI [28]. Included patients received a median number 
of 3 dalbavancin administrations and in most of cases this agent 
was chosen because of its pharmacokinetic properties in order to 
allow a treatment in an outpatient setting. In most patients, dalba-
vancin turned out to be safe and effective and resulted in the lack 
of clinical signs of infection at 90 days after last administration. Two 
patients with PJI experienced a treatment failure, two patients (one 
for each indication) had a lethal course of disease and one patient 
with osteomyelitis was excluded from the statistical analysis 
because of severe adverse effects related to the second dose of 
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dalbavancin. Another group treated 64 patients with dalbavancin, 
including 19 patients with osteomyelitis and 45 patients with PJI 
[15]. In this case, the most frequently isolated pathogen was 
Staphylococcus epidermidis followed by MRSA and in most cases 
the reason for the switch to dalbavancin was the simplification of 
the antimicrobial regimen. Among the patients with osteomyelitis, 
73,7% (n = 14) reached a clinical success and 15.8% (n = 3) clinically 
improved after a median follow-up of 164 days, while in two 
patients the treatment with dalbavancin was declared ineffective. 
Among the patients with PJI, the implant was retained in 52.3% of 
cases (n = 23) with a clinical success in 15 and an improvement in 8 
patients. On the contrary, the implant was removed in 47.7% of 
cases (n = 21) with a clinical success in 16 and an improvement in 4 
patients; a patient with PJI and removal of the implant experienced 
a clinical failure, while another patient with PJI could not be 
included in the efficacy analysis because of a premature loss in 
the follow-up [15]. Bartoletti and coworkers used dalbavancin in 
the treatment of 15 patients with post-surgical deep sternal 
wound infections, obtaining a 93% success rate after a 6-months 
follow-up [29]. A single randomized controlled trial (RCT) so far 
evaluated the efficacy of dalbavancin in the treatment of osteo-
myelitis: 80 adult patients with a first episode of osteomyelitis were 
randomized to dalbavancin (n = 70, 1500 mg on days 1 and 8) or 
standard of care (n = 10, the most common regimens were vanco-
mycin for 29–30 days or vancomycin for 5–16 days and switch to 
linezolid or levofloxacin to complete 29 days of therapy) [30]. The 
most commonly isolated pathogens were Staphylococcus aureus, 
coagulase-negative Staphylococci and anaerobes. A clinical success 
was observed at follow-up in 97% of patients (n = 65) in the 
dalbavancin group and in 88% of patients (n = 7) in the SOC 
group, while five patients were not included in the statistical 
analysis because of a change of treatment due to isolation of 
only Gram-negative bacteria. Analogous success rates were 
reported at the 6-months and 1-year follow-up controls.
3.3. Infective endocarditis
Infective endocarditis (IE) is an infectious process involving the 
endocardial surface of intracardial structures, such as heart 
valves, both native or prosthetic, or intracardial implantable 
medical devices. Based on the clinical manifestations of the 
disease, IE can be further classified in acute or subacute. While 
acute endocarditis generally present with a sudden onset of 
fever or systemic complications, subacute endocardial infec-
tions are often misdiagnosed because of unspecific symptoms 
lasting over weeks or months such as fatigue, dyspnea or 
weight loss. The most commonly isolated pathogen in blood 
cultures of patients with IE is Staphylococcus aureus, followed 
by Viridians group streptococci and by enterococci which are 
typical for the elderly. Coagulase negative Staphylococci are 
Table 1. Dalbavancin in the treatment of bone and joint infections.
Reference Type of study Included patients
Dose and duration of dalbavancin 
treatment % Outcome Adverse events
Study 
reference
Bouza et al., 
2018
Retrospective 12 OM, 20 PJI Varying: mean of 4 doses (range 1–9), 
3-week duration (range 1–24)






Retrospective 34 OM, 8 PJI Varying: median doses 8 weeks 
(range 4–32)
65% for OM, 50% for 
SD and 75% for PJI
Acute reactions such as 
exanthema or 
hyperglycemia, but 
















Retrospective 15 sternal OM post- 
cardiac surgery






Retrospective 31 OM Varying: median of 3 doses (range 
1–14)
93% for OM None [49]
Bork et al., 
2019
Retrospective 13 OM, 1 PJI Varying: median of 3 doses (IQR 4.5) 46% for OM 10% (One secondary to acute 
kidney 







Retrospective 15 OM Varying: median of 1 dose (IQR: 1–2) 92% 11%, Mild [13]
Morata et al., 
2019
Retrospective 19 OM, 45 PJI Varying: median of 5 doses (IQR 3–8) 89.5% for OM; 69% for 
PJI
11%, Mild [15]




Dalbavancin: 70 vs 
SOC: 10
1500 mg day 1 + 1500 mg day 8 96% Dalbavancin vs 
88% SOC
None [30]
Bai et al., 
2020
Retrospective 29 OM 1500 mg, maximum number of 
dalbavancin administration 7 doses







Dalba: 11 OM vs 
SOC 11 OM
Range 3000 mg and 7500 mg, median 





OM,osteomyelitis; PJI,prosthetic joint infection; SOC,standard of care. 
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a leading cause of infective endocarditis involving prosthetic 
valves or intracardiac devices. Due to frequent antibiotic resis-
tance and difficult medication penetration into bacterial endo-
cardial vegetations, IE often require a combined and 
prolonged intravenous antimicrobial therapy and debride-
ment and valve replacement surgery [31,32]. Dalbavancin is 
not currently approved for the treatment of IE; nevertheless, 
because of its activity spectrum and pharmacokinetic proper-
ties, it may be a promising alternative in this clinical setting, 
reducing hospitalization duration and assistance costs.
Several retrospective studies report the use of dalbavancin in 
treating patients with an infective endocarditis, including both 
native and prosthetic valves infections (Table 2). The largest cohort 
has been included by an Austrian group, who administered dalba-
vancin to 27 patients, including 16 patients with native valve, 6 
patients with prosthetic valve and 5 with intracardiac implantable 
device IE. In 24 cases, dalbavancin was used as a sequential treat-
ment after negative blood cultures were achieved, whereas 3 
patients received dalbavancin as primary treatment [35]. The 
most frequent reason for the switch to dalbavancin in the sequen-
tial group was the possibility to discharge patients and continue 
the treatment in an outpatient setting. Considering all patients 
included, the mean duration of dalbavancin treatment was 
6 weeks. A clinical success was observed in 92.6% of patients 
(n = 25) based on the lack of persistence or relapse of infection at 
the 6-months follow-up. One patient with Enterococcus faecalis 
prosthetic valve IE died after the first dose of dalbavancin, while 
in another patient with a poorly surgically controlled IE, dalbavan-
cin was discontinued because of clinical and microbiological fail-
ure. Patients with IE and treated with dalbavancin were also 
included in two other studies and an overall satisfactory clinical 
success was observed [14,28]. Another group evaluated dalbavan-
cin efficacy in 27 patients with severe Gram-positive infections, 
including 8 IE, in order to facilitate earlier hospital discharge [33]. In 
all cases, dalbavancin was administered to complete the planned 
antibiotic course after an initial inpatient treatment. Among the 
patients with IE, six had no clinical or microbiological evidence of 
active infection within 90 days of the last dalbavancin dose, 
whereas two had no documented clinical encounters. Lastly, 
a recent work reports a successful long-term suppressive dalba-
vancin treatment in a patient with a Staphylococcus epidermidis 
and Streptococcus mitis infection of aortic valve and tubular 
ascending aorta bioprosthetic devices who was not considered 
eligible for valve replacement surgery and who did not tolerate 
oral antibiotic therapy [37]. In this case, the administration regimen 
was scheduled according to the serum bactericidal activity (SBA) 
levels which were performed immediately before each dalbavan-
cin dose. The authors report that this long-term suppressive anti-
microbial treatment was well tolerated and achieved an 
improvement of clinical conditions with progressive disappear-
ance of the vegetative lesions on transesophageal echocardiogra-
phy and reduction of focal uptake on PET/TC scans.
4. Expert opinion
4.1. ABSSIs
Dalbavancin should be evaluated in the treatment of moder-
ate to severe ABSSSIs, whereas other antimicrobial agents, 
such as beta-lactams, should still be considered the first 
option in MSSA-likely mild cutaneous or subcutaneous infec-
tions, as erysipelas. Dalbavancin could be a choice in purulent 
infections, if adequately associated to surgical debridement. 
ABSSSIs can be caused by pathogens other than Gram-positive 
bacteria; thus, an etiologic diagnosis should be pursued before 
considering administration of dalbavancin. Specifically, some 
clinical signs may suggest Gram-negative or anaerobic etiol-
ogy, thus excluding dalbavancin: infection close to the peri-
neal region, diabetic foot infections or the presence of 
refractory ulcers. On the contrary, if disease or patient- 
related signs may suggest a MRSA etiology, dalbavancin 
administration should strongly be supported [43].
Some groups of patients may mostly benefit from dalba-
vancin, whose administration does not require long-term 
intravenous catheters or a prolonged hospitalization, as onco-
logic patients, recent or active intravenous drug users, patients 
with a lack of support at home, homeless, recent or active 
alcohol abuse, or severely burned patients [11].
Furthermore, the pharmacokinetic profile of dalbavancin 
may allow the administration for ABSSSIs in three logistic 
settings. The first is the emergency department (ER). As sup-
ported by preliminary data, a patient being evaluated in the 
ER for a moderate-to-severe cutaneous infection could be 
directly treated with dalbavancin, immediately discharged 
and followed up either via the outpatient clinic, by the general 
practitioner or through telehealth programs [36,37]. This 
option would avoid unnecessary hospitalization, thus reducing 
assistance costs and minimizing the risk of nosocomial infec-
tions. Nonetheless, physicians working in ER are rarely experi-
enced in dealing with second-level antimicrobials and the 
uninterrupted presentation of patients requiring urgent care 
often makes the ER an inappropriate setting for long-acting 
medications. Therefore, dalbavancin should be administered 
only under the supervision of an ID specialist. Moreover, the 
implementation of ASPs through a multi-disciplinary network 
between ID specialist and ER departments may improve the 
prescription of long-acting antimicrobial agents. Secondly, 
dalbavancin could be easily administered in a dedicated out-
patient clinic, where the supervision of the ID specialist is 
strongly recommended. Lastly, many evidences highlighted 
that dalbavancin can shorten the length of hospital stay 
through the achievement of an early discharge [38]. Indeed, 
in patients with comorbidities and requiring an inpatient 
treatment, dalbavancin could be initiated to avoid prolonged 
hospitalization and allow early discharge of the patients.
4.2. Osteomyelitis and PJI
The main limitation of the current evidence on the use of 
dalbavancin in the treatment of osteomyelitis and PJI is the 
retrospective nature of the data. Nonetheless, the lack of an 
approved indication for the drug in these contexts severely 
hampers the systematic evaluation of dalbavancin in clinical 
studies and the design of prospective RCT. Furthermore, the 
possibility to deduce conclusive evidence from the above- 
mentioned studies is hindered by some methodological lim-
itations: inclusion criteria of patients, outcome measures and 
follow-up durations are extremely heterogenous among the 
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different studies. Many different administration regimens are 
reported. Moreover, the overall number of patients treated 
with dalbavancin is low and the only RCT on this matter is 
inappropriately designed (7:1 randomization). Furthermore, 
under the definition of osteomyelitis a broad spectrum of 
different entities is included, such as spondylodiscitis, hema-
togenous osteomyelitis or contiguity osteomyelitis. The effi-
cacy of dalbavancin in any different subtypes should be 
separately considered. As for PJIs, the removal of the infected 
implant is a fundamental therapeutic step and data based on 
patients in whom the implant was retained should be sepa-
rately considered. A final limitation is the lack of a systematic 
monitoring of plasma concentrations of dalbavancin and 
a correlation with the SBA levels, which may be useful in 
monitoring therapeutic efficacy [39]. Therapeutic drug moni-
toring (TDM) could also provide a helpful feedback in under-
standing how the active moiety vary over time. Considering 
the current limitations in using dalbavancin in RCTs for the 
treatment of osteomyelitis and PJI, the design of robust retro-
spective studies may increase the knowledge on the efficacy 
of this agent in these clinical settings. For this purpose, the 
definition of homogenous inclusion criteria, administration 
regimens, outcome measures, and follow-up durations is 
extremely urgent. Spondylodiscitis could represent an ideal 
model for the evaluation of a possible use of dalbavancin, 
since a microbiological diagnosis is usually achieved, and 
a targeted therapy could be easily administered.
Overall, on the basis of the so far available theoretical and 
experimental data, dalbavancin could represent, alone or in 
combination with beta-lactams, a valid option for the treat-
ment of osteomyelitis and PJI and could allow, due to its 
unique pharmacokinetic properties, an early discharge of 
patients.
4.3. Infective endocarditis
The two discussed uses of dalbavancin in IE would not fully 
take advantage of the pharmacokinetic and pharmacody-
namic properties of the molecule. Indeed, dalbavancin 
showed a very effective bactericidal activity against the most 
frequently isolated Gram-positive bacteria in IE patients and 
has the potentiality to become a first-line option in the ther-
apy of IE [40,41]. Furthermore, severe subacute Gram-positive 
infections often require prolonged antimicrobial therapies, 
which are extremely expensive and rarely possible in the out-
patient care (difficulty of intravenous access and limited evi-
dence for the safety and efficacy of oral medications). The 
latter was addressed in a recent study, highlighting how in 
patients with endocarditis in stable condition, changing to oral 
antibiotic treatment was noninferior to continued intravenous 
antibiotic treatment [42]. However, these strategies do not 
adequately serve vulnerable populations (i.e. people who use 
drugs, those with difficulties to comply to unsupervised treat-
ment or with complicating life circumstances), and dalbavan-
cin may represent a modern alternative and its use may 
overcome many of the barriers that complicate traditional 
treatment approaches, even if some aspects should be further 
addressed (i.e lack of prospective data regarding efficacy in 
serious infections and a narrow indication) [43].
Notably, the future role of dalbavancin could become more 
important considering the open issues in the treatment of 
Gram-positive subacute infections. These include the spread-
ing of isolates resistant to beta-lactams, vancomycin or dapto-
mycin, the concerns on aminoglycosides toxicity in 
combination therapies, especially in old patients. Moreover, 
further studies are required in order to define specific sub-
groups of patients who could benefit from a first-line dalba-
vancin therapy alone or in combination with beta-lactams. For 
example, patients with an MRSA IE could be treated with 
surgical debridement or valve replacement followed by an 
extremely effective antimicrobial therapy with dalbavancin 
and then complete the antibiotic course with a less bacterici-
dal agent. Nonetheless, a systematic use of dalbavancin for IE 
patients is feasible only if prelimin ary pharmacokinetic studies 
are conducted, in order to evaluate the relationship between 
different dosing regimens and the dalbavancin penetration 
rate into endocardial vegetations and the achievable bacter-
icidal activity. Indeed, treating IE is often hard and requires 
high-dosed antimicrobial agents, making toxic effects more 
probable. Dalbavancin pharmacokinetic studies are thus 
urgent in order to adopt adequate administration regimens 
and prevent clinical failures or antimicrobial resistance devel-
opment. In this clinical indication, the concomitant TDM and 
SBA analysis could be useful in monitoring the in vivo activity 
of the drug.
On the basis of the so far available experimental data, 
dalbavancin could represent a valid option for the treatment 
of IE as a sequential therapy to allow early discharge of 
patients or as a long-term suppressive treatment in patients 
who could not benefit from a debridement surgery or from an 
oral antimicrobial regimen. Notably, long-term suppressive 
therapy is a last option in patients with chronic infections 
and should be carefully used. When adopted, it can reduce 
the hospitalization and avoid the risk of acquiring healthcare- 
related infections in fragile patients [44]. Attention must be 
paid to the chosen antimicrobial agent in terms of safety, 
compliance and costs. Dalbavancin, with its unique pharma-
cokinetic profile, and great tolerability, as well as pharmacoe-
conomic advantages in terms of length of hospitalization, is an 
attractive option for long-term suppressive therapy, and, 
depending on the clinical scenario and alternative treatment 
options, use may be cost-effective [45,46].
5. Conclusion
As documented by RCT and real-life experience, dalbavancin 
showed to be highly effective in patients with ABSSSIs. Within 
this context, dalbavancin could be administered in an out-
patient setting if a strict supervision by an ID specialist can 
be guaranteed and the patient can be adequately followed up. 
The use of dalbavancin in the ER requires an implementation 
of ASPs, an adequate formation of emergency physicians and 
a constant consultation with an ID specialist. Lastly, the possi-
bility to administer dalbavancin to facilitate earlier hospital 
discharge remains a valid option.
Although not formally approved by regulatory agencies, 
several real-life experiences of dalbavancin use in 
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osteomyelitis, PJI and IE are reported. Many limitations are 
present in the currently available data; however, dalbavancin 
could unequivocally represent a valid option in these contexts 
due to its pharmacokinetic and pharmacodynamic properties 
such as the prolonged plasmatic half-life and the potent bac-
tericidal activity against susceptible Gram-positive bacteria. 
Considering the current limitations in designing prospective 
studies, a definition of homogenous parameters to include 
patients in retrospective studies and to evaluate the clinical 
efficacy of the molecule should be carried out, leading to 
a more robust evidence to increase the use of dalbavancin in 
indications other than ABSSSIs.
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